Anastasios Gianakakos Sells 5,000 Shares of Myokardia Inc (NASDAQ:MYOK) Stock

Myokardia Inc (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $65.02, for a total value of $325,100.00. Following the transaction, the chief executive officer now directly owns 90,864 shares in the company, valued at approximately $5,907,977.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anastasios Gianakakos also recently made the following trade(s):

  • On Monday, November 4th, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $59.07, for a total value of $295,350.00.
  • On Wednesday, October 2nd, Anastasios Gianakakos sold 4,000 shares of Myokardia stock. The stock was sold at an average price of $52.28, for a total value of $209,120.00.
  • On Wednesday, September 11th, Anastasios Gianakakos sold 1,000 shares of Myokardia stock. The stock was sold at an average price of $55.00, for a total transaction of $55,000.00.

Shares of MYOK stock opened at $67.12 on Friday. The stock has a market cap of $3.10 billion, a PE ratio of -38.14 and a beta of 2.07. Myokardia Inc has a 52-week low of $39.01 and a 52-week high of $68.06. The business has a 50-day simple moving average of $59.23 and a 200-day simple moving average of $53.62.

Myokardia (NASDAQ:MYOK) last issued its quarterly earnings data on Monday, November 11th. The biotechnology company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.91) by $0.57. As a group, research analysts expect that Myokardia Inc will post -4.6 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Myokardia by 6.6% in the second quarter. Vanguard Group Inc. now owns 3,715,719 shares of the biotechnology company’s stock valued at $186,307,000 after buying an additional 228,576 shares during the last quarter. BlackRock Inc. grew its position in shares of Myokardia by 19.1% in the second quarter. BlackRock Inc. now owns 3,607,728 shares of the biotechnology company’s stock valued at $180,892,000 after purchasing an additional 577,590 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Myokardia by 3.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,516,869 shares of the biotechnology company’s stock valued at $176,336,000 after purchasing an additional 132,654 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Myokardia by 2.5% in the second quarter. Farallon Capital Management LLC now owns 2,000,000 shares of the biotechnology company’s stock valued at $100,280,000 after purchasing an additional 49,722 shares during the last quarter. Finally, Perceptive Advisors LLC increased its holdings in shares of Myokardia by 11.3% in the second quarter. Perceptive Advisors LLC now owns 1,100,511 shares of the biotechnology company’s stock valued at $55,180,000 after purchasing an additional 112,000 shares during the last quarter.

Several research analysts recently issued reports on the company. Wedbush increased their price objective on Myokardia from $87.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Maxim Group reiterated an “average” rating on shares of Myokardia in a report on Monday, October 28th. BidaskClub upgraded Myokardia from a “hold” rating to a “buy” rating in a report on Saturday, November 30th. Guggenheim started coverage on shares of Myokardia in a report on Thursday, September 19th. They set a “buy” rating on the stock. Finally, Cowen reaffirmed a “buy” rating and issued a $73.00 price target on shares of Myokardia in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $76.89.

Myokardia Company Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

See Also: Bond

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.